-
公开(公告)号：US20230308835A1
公开(公告)日：2023-09-28
申请号：US17640291
申请日：2020-09-04
Applicant: NOVARTIS AG
Inventor： Sebastien IRIGARAY , Laurent KLEIN , Darko SKEGRO , Marco VILLANI , Karl WELZENBACH
Abstract: A determination is made that a mobile device is associated with a reference activity of a user based on motion, orientation, rotational, magnetic field, and/or location data provided by sensors of the device. Activity data associated with the reference activity is obtained from the sensor-provided data. The activity data is recorded on the device for a configured period of time after which it is determined that the device is no longer performing the reference activity. The retained activity data for the reference activity is sent from the device to a network-based behavior analyzer when a network connection is available from the device. The network-based behavior analyzer derives user behaviors for the reference activity based on the activity data.
-
公开(公告)号：US20230220048A1
公开(公告)日：2023-07-13
申请号：US17640295
申请日：2020-09-04
Applicant: NOVARTIS AG
Inventor： Sebastien IRIGARAY , Laurent KLEIN , Darko SKEGRO , Marco VILLANI , Karl WELZENBACH
IPC: C07K14/765 , C07K14/485 , C07K14/705
CPC classification number: C07K14/765 , C07K14/485 , C07K14/7056 , C07K2319/30 , C07K2319/31 , A61K38/00
Abstract: The present invention relates to fusion proteins suitable for use as a medicament or research tool. Therapeutic uses of the fusion proteins may include the prevention or treatment of acute or chronic inflammatory and immune system-driven organ and micro-vascular disorders, for example, acute kidney injury, acute myocardial infarction, acute respiratory distress or chronic obstructive pulmonary disease fibrosis and other organ injuries resulting from tissue trauma and acute and chronic injury.
-
公开(公告)号：US20250011428A1
公开(公告)日：2025-01-09
申请号：US18705653
申请日：2022-10-27
Applicant: Novartis AG
Inventor： Justine Celine Patricia GUYOT , Sebastien IRIGARAY , Darko SKEGRO
IPC: C07K16/28
Abstract: The present invention describes engineered immunoglobulin IgG Fc regions by transferring structural elements, several CH2 inter-chain disulfide bonds, from IgA to IgG immunoglobulin. The disclosed Fc variants created thereof exhibit marked reductions or complete abrogation of interaction of the engineered Fc with FcγR and C1q while retaining natural ability to interact with FcRn at acidic pH. Silenced Fc molecules disclosed are in comparable expression and purification yields and improved or maintained thermostability compared to wild-type Fc, thereby limiting the propensity for aggregation. In addition, the disclosed Fc variant silencing mutations are capable of reducing or compensating destabilizing effects of other half-life extending or chain pairing facilitating Fc mutations.
-
Patent Agency Ranking
公开(公告)号：US20230242647A1
公开(公告)日：2023-08-03
申请号：US17997482
申请日：2021-04-29
Applicant: Novartis AG
Inventor： John BLANKENSHIP , Justine Celine Patricia GUYOT , Brian HOLMBERG , Sebastien IRIGARAY , Darko SKEGRO
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/283 , A61K39/3955 , A61P35/00 , A61K2039/505
Abstract: The present invention provides engineered immunoglobulins or fragments thereof and methods for their preparation and uses. The engineered immunoglobulins have been derived from human IgG1 and engineered to confer Fc alpha receptor binding ability. In addition, the engineered IgG1 immunoglobulins or fragments thereof can retain binding to Fc gamma receptors and/or FcRn.
-
公开(公告)号：US20230295291A1
公开(公告)日：2023-09-21
申请号：US18049747
申请日：2022-10-26
Applicant: Novartis AG
Inventor： Regis CEBE , Sebastien IRIGARAY , Darko SKEGRO
CPC classification number: C07K16/244 , C07K16/2863 , C07K2317/31 , C07K2317/522 , C07K2317/55 , C07K2317/50 , C07K2317/60 , C07K2317/66
Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.
-
公开(公告)号：US20230265160A1
公开(公告)日：2023-08-24
申请号：US17640293
申请日：2020-09-04
Applicant: NOVARTIS AG
Inventor： Sebastien IRIGARAY , Laurent KLEIN , Darko SKEGRO , Marco VILLANI , Karl WELZENBACH
IPC: C07K14/705 , C07K14/765 , A61P29/00
CPC classification number: C07K14/70546 , A61P29/00 , C07K14/765 , C07K2319/21
Abstract: The present invention relates to fusion proteins suitable for use as a medicament or research tool. Therapeutic uses of the fusion proteins may include the prevention or treatment of acute or chronic inflammatory and immune system-driven organ and micro-vascular disorders, for example, acute kidney injury, acute myocardial infarction, acute respiratory distress or chronic obstructive pulmonary disease fibrosis and other organ injuries resulting from tissue trauma and acute and chronic injury.
-
公开(公告)号：US20230167193A1
公开(公告)日：2023-06-01
申请号：US17997485
申请日：2021-04-29
Applicant: Novartis AG
Inventor： John BLANKENSHIP , Justine Celine Patricia GUYOT , Brian HOLMBERG , Sebastien IRIGARAY , Darko SKEGRO
IPC: C07K16/30
CPC classification number: C07K16/30 , C07K2317/732 , A61K2039/505
Abstract: The present invention provides an Fc variant of a parent IgA Fc polypeptide, wherein the Fc variant exhibits altered binding to FcαRs, wherein the Fc variant comprises at least one amino acid modification in the Fc region of the parent Fc polypeptide.
-
公开(公告)号：US20190382475A1
公开(公告)日：2019-12-19
申请号：US16483185
申请日：2018-03-01
Applicant: Novartis AG
Inventor： Regis CEBE , Sebastien IRIGARAY , Darko SKEGRO
Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.01 seconds)
